Steven Albelda

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells
    Saskia J A M Santegoets
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Transl Med 11:37. 2013
  2. pmc Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness
    Jarrod D Predina
    Department of Surgery, Thoracic Surgery Research Laboratory, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Hematol Oncol 5:34. 2012
  3. pmc The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells
    Jon G Quatromoni
    Division of Thoracic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
    BMC Immunol 14:30. 2013
  4. pmc Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major trauma
    Melanie Rushefski
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, USA
    BMC Med Genet 12:77. 2011
  5. ncbi Role for platelet-endothelial cell adhesion molecule-1 in macrophage Fcgamma receptor function
    Steven M Albelda
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Respir Cell Mol Biol 31:246-55. 2004
  6. ncbi Gene therapy for lung disease: hype or hope?
    S M Albelda
    University of Pennsylvania Medical Center, Philadelphia, USA
    Ann Intern Med 132:649-60. 2000
  7. ncbi Gene therapy for lung neoplasms
    Steven M Albelda
    Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Clin Chest Med 23:265-77. 2002
  8. ncbi Pulmonary genetics, genomics, and gene therapy: conference summary
    Steven M Albelda
    Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Chest 121:105S-110S. 2002
  9. ncbi Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
    Eiji Suzuki
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Cancer Res 11:6713-21. 2005
  10. ncbi Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma
    Arminder S Jassar
    Thoracic Oncology Research Laboratory, University of Pennsylvania Medical School, Philadelphia, 19104, USA
    Cancer Res 65:11752-61. 2005

Research Grants

  1. TRAINING IN PULMONARY IMMUNOLOGY
    Steven Albelda; Fiscal Year: 2007
  2. The Role of PECAM in Models of Lung Injury
    Steven Albelda; Fiscal Year: 2005
  3. The Role of PECAM in Models of Lung Injury
    Steven Albelda; Fiscal Year: 2004
  4. The Role of PECAM in Models of Lung Injury
    Steven Albelda; Fiscal Year: 2003
  5. The Role of PECAM in Models of Lung Injury
    Steven Albelda; Fiscal Year: 2002
  6. PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION
    Steven Albelda; Fiscal Year: 2002
  7. PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION
    Steven Albelda; Fiscal Year: 2001
  8. PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION
    Steven Albelda; Fiscal Year: 2000
  9. HUMAN-MOUSE CHIMERAS--A MODEL FOR VASCULAR CELL BIOLOGY
    Steven Albelda; Fiscal Year: 1993
  10. PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION
    Steven Albelda; Fiscal Year: 1999

Detail Information

Publications80

  1. pmc IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells
    Saskia J A M Santegoets
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Transl Med 11:37. 2013
    ..Here, we have compared the effects of IL-2, -15 and -21 cytokines on the expansion and activation of TIL from single-cell suspensions of non-small cell lung cancer, ovarian cancer and melanoma...
  2. pmc Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness
    Jarrod D Predina
    Department of Surgery, Thoracic Surgery Research Laboratory, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Hematol Oncol 5:34. 2012
    ..We hypothesized that cytoreductive surgery could control these immunosuppressive networks and restore the potency of immunotherapy in advanced disease scenarios...
  3. pmc The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells
    Jon G Quatromoni
    Division of Thoracic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
    BMC Immunol 14:30. 2013
    ..We hypothesized that TGF-β is necessary for the anti-tumor effects of cytotoxic CD8+ T lymphocytes (CTLs) during the early stages of tumor initiation...
  4. pmc Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major trauma
    Melanie Rushefski
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, USA
    BMC Med Genet 12:77. 2011
    ..Little is known about genetic variation within the PRDX6 gene and its association with acute lung injury (ALI). In this study we sequenced the PRDX6 gene to uncover common variants, and tested association with ALI following major trauma...
  5. ncbi Role for platelet-endothelial cell adhesion molecule-1 in macrophage Fcgamma receptor function
    Steven M Albelda
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Respir Cell Mol Biol 31:246-55. 2004
    ..Although PECAM-1 may not be required for transmigration of leukocytes into the alveolar space in many forms of complex lung inflammation, it is important in the function of Fcgamma receptors on alveolar macrophages...
  6. ncbi Gene therapy for lung disease: hype or hope?
    S M Albelda
    University of Pennsylvania Medical Center, Philadelphia, USA
    Ann Intern Med 132:649-60. 2000
    ..Recent advancements in understanding of the molecular basis of lung disease and the development of improved vector systems make it likely that gene therapy will be an important tool for the 21st-century clinician...
  7. ncbi Gene therapy for lung neoplasms
    Steven M Albelda
    Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Clin Chest Med 23:265-77. 2002
    ..Given the progress so far, there is little doubt that gene therapy will become a key approach for the treatment of thoracic malignancies in the near future...
  8. ncbi Pulmonary genetics, genomics, and gene therapy: conference summary
    Steven M Albelda
    Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Chest 121:105S-110S. 2002
  9. ncbi Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
    Eiji Suzuki
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Cancer Res 11:6713-21. 2005
    ..Elimination of these myeloid suppressor cells may thus significantly improve antitumor responses and enhance effects of cancer immunotherapy, although to date few practical options exist...
  10. ncbi Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma
    Arminder S Jassar
    Thoracic Oncology Research Laboratory, University of Pennsylvania Medical School, Philadelphia, 19104, USA
    Cancer Res 65:11752-61. 2005
    ..Given these properties, DMXAA might also be useful in boosting other forms of immunotherapy...
  11. pmc Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy
    Samuel Kim
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6160, USA
    Cancer Res 68:10247-56. 2008
    ..IFN-beta immune-activating or Ad.E7 vaccination therapy. The addition of TGF-beta blocking agents in clinical trials of immunotherapies may increase efficacy...
  12. ncbi Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing
    Rainer Wiewrodt
    Department of Medicine, Philadelphia, Pennsylvania 19194, USA
    Cancer Gene Ther 10:353-64. 2003
    ..HSV-tk when GCV was administered. The use of adenovirus-mediated gene transfer of both tk mutants dm30-tk and sr39-tk for cancer suicide gene therapy should provide a more effective and safer alternative to wild-type HSV-tk...
  13. ncbi Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma
    Robert J Kruklitis
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    J Thorac Cardiovasc Surg 127:123-30. 2004
    ....
  14. ncbi Dissociation between alveolar transmigration of neutrophils and lung injury in hyperoxia
    Sandra Perkowski
    School of Veterinary Medicine, University of Pennsylvania, 421 Curie Blvd, BRB II III, Philadelphia, 19104, USA
    Am J Physiol Lung Cell Mol Physiol 291:L1050-8. 2006
    ..Blocking PMN recruitment did not prevent lung injury, supporting dissociation between PMN infiltration and lung injury during hyperoxia in mice...
  15. ncbi Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad.IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer
    Michael J Wilderman
    Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, BRB II III, 421 Curie Boulevard, Philadelphia, PA 19104 6160, USA
    Mol Ther 13:910-7. 2006
    ..Therapeutic application of anti-inflammatory therapy in immuno-gene therapy strategies should thus be undertaken with caution...
  16. pmc Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
    Zvi G Fridlender
    Thoracic Oncology Research Laboratory, 1016B ARC, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    Cancer Cell 16:183-94. 2009
    ..Together, these data suggest that TGF-beta within the tumor microenvironment induces a population of TAN with a protumor phenotype. TGF-beta blockade results in the recruitment and activation of TANs with an antitumor phenotype...
  17. ncbi Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine
    Andrew R Haas
    Thoracic Oncology Research Laboratory, Philadelphia, Pennsylvania 19104 6160, USA
    Clin Cancer Res 12:214-22. 2006
    ..This study shows that the effectiveness of a cancer vaccine can be significantly improved by adding COX-2 inhibition...
  18. pmc Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery
    Tomoyuki Tanaka
    Department of Surgery, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Ann Surg 241:168-78. 2005
    ..To investigate the uses and limitations of cyclooxygenase- (COX) 2 inhibition using clinically relevant doses of oral rofecoxib in the treatment of murine models of non-small-cell lung cancer (NSCLC)...
  19. ncbi Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung
    Michael J Wilderman
    Thoracic Oncology Research Laboratory, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19014 6160, USA
    Cancer Res 65:8379-87. 2005
    ..IFNbeta. These studies, showing remarkable antitumor activity in this orthotopic lung cancer model, provide strong preclinical support for a trial of Ad.IFNbeta to treat human non-small cell lung cancer...
  20. ncbi The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes
    Africa Wallace
    Thoracic Oncology Research Laboratory, Department of Medicine, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Cancer Res 67:7011-9. 2007
    ..DMXAA thus has the ability to activate tumor-specific CD8(+) T cells through multiple pathways that include induction of tumor cell death, release of stimulatory cytokines, and direct activation of dendritic cells...
  21. ncbi Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity
    Eiji Suzuki
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:5907-18. 2004
    ..The purpose of this study was to explore the possible therapeutic utility of TGF-beta blockade on MM...
  22. ncbi Interferon beta adenoviral gene therapy in a patient with ovarian cancer
    Daniel H Sterman
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA
    Nat Clin Pract Oncol 3:633-9. 2006
    ..Diagnosis Stage IV ovarian cancer with malignant ascites and pleural effusion. Management Tunneled pleural catheter and intrapleural adenoviral-mediated interferon beta gene therapy...
  23. ncbi A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1
    Silvia Muro
    Department of Physiology, University of Pennsylvania School of Medicine, B 400 Richards 6085, 3700 Hamilton Walk, Philadelphia, PA 19104, USA
    J Cell Sci 116:1599-609. 2003
    ....
  24. ncbi Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects
    Eiji Suzuki
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 6:880-5. 2007
    ..These data raise the exciting possibility that GEM may be a useful agent in combination with various types of tumor immunotherapy...
  25. pmc Targeted detoxification of selected reactive oxygen species in the vascular endothelium
    Vladimir V Shuvaev
    Institute for Environmental Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6068, USA
    J Pharmacol Exp Ther 331:404-11. 2009
    ..Therefore, the use of endothelial cell-targeted antioxidants identifies the key specific species of ROS involved in various forms of vascular disease and holds promise for the mechanistically tailored treatment of these pathologies...
  26. pmc Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy
    Vassiliki Saloura
    Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Hum Gene Ther 21:51-64. 2010
    ..However, it may be feasible to prescreen individual susceptibility to VSV.IFN-beta by immunostaining for the presence of p48 protein...
  27. ncbi PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress
    Melpo Christofidou-Solomidou
    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6068, USA
    Am J Physiol Lung Cell Mol Physiol 285:L283-92. 2003
    ..g., for augmentation of antioxidant defense in the pulmonary endothelium and treatment of ALI...
  28. doi Gene therapy for mesothelioma and lung cancer
    Anil Vachani
    University of Pennsylvania, 1016B Abramson Research Center, 3615 Civic Center Blvd, Philadelphia, PA 19104 6160, USA
    Am J Respir Cell Mol Biol 42:385-93. 2010
    ..This review will consider the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies...
  29. pmc Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor
    Yangbing Zhao
    Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine and Thoracic Oncology Research Laboratory and Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6160, USA
    Cancer Res 70:9053-61. 2010
    ..This approach may increase the therapeutic index of T cells engineered to express powerful activation domains without the associated safety concerns of integrating viral vectors...
  30. ncbi PECAM-1-dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization
    CHRISTOPHER D O'BRIEN
    Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Blood 101:2816-25. 2003
    ....
  31. ncbi Cytokine gene therapy for malignant pleural mesothelioma
    Anil Vachani
    Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    J Thorac Oncol 2:265-7. 2007
  32. ncbi Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma
    Jason D Christie
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Crit Care Med 36:2794-800. 2008
    ..We tested the association of MYLK gene variation in the development of acute lung injury in major trauma patients...
  33. pmc Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium
    Vladimir V Shuvaev
    Institute for Environmental Medicine, School of Medicine, University of Pennsylvania Medical Center, 36th Street and Hamilron Walk, Philadelphia, PA 19104, USA
    J Control Release 118:235-44. 2007
    ..Understanding the nature of such "modulating biological factors" will hopefully allow optimization and ultimately applications of drug targeting for "individualized" pharmacotherapy...
  34. pmc Advanced glycation end products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for advanced glycation end products
    NILAM S MANGALMURTI
    Department of Medicine, Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia 19104, USA
    Transfusion 50:2353-61. 2010
    ....
  35. ncbi A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses
    Daniel H Sterman
    Thoracic Oncology Gene Therapy Program and Abramson Family Cancer Research Institute, University of Pennsylvania Medical Center, Philadelphia, PA 19104 4283, USA
    Clin Cancer Res 13:4456-66. 2007
    ..IFN-beta) in patients with malignant pleural mesothelioma (MPM) and metastatic pleural effusions (MPE)...
  36. ncbi Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy
    Peter DeLong
    Thoracic Oncology Laboratory, 8th Floor BRB II III, University of Pennsylvania Medical Center, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Cancer Res 63:7845-52. 2003
    ....
  37. doi B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models
    Samuel Kim
    Department of Surgery and Medicine, Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    J Immunother 31:446-57. 2008
    ..These studies raise the possibility that B-cell depletion may be a useful adjunct in human immunotherapy trials...
  38. ncbi Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy
    Daniel H Sterman
    Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, PA 19104 4283, USA
    Clin Cancer Res 11:7444-53. 2005
    ..HSVtk) in combination with systemic ganciclovir...
  39. ncbi Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling
    Sunil Singhal
    Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 2:291-8. 2003
    ..e., cdc2, cullin 4A, ZAC, p57, DP-1, GADD45, PISSLRE, cdc20) nor in any other tumors (i.e., cyclin F, cullin 5, p34). These results identified several potential cell cycle genes altered in lung cancer...
  40. ncbi Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma
    Daniel H Sterman
    Thoracic Oncology Research Laboratory, Interventional Pulmonology Program, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 4283, USA
    Respirology 10:266-83. 2005
    ..Over the past decade, significant advances have been made on several fronts that have improved the ability to diagnose a stage, define prognosis, and treat malignant pleural mesothelioma...
  41. pmc A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions
    Daniel H Sterman
    Section of Interventional Pulmonology and Thoracic Oncology, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 4283, USA
    Mol Ther 18:852-60. 2010
    ..This approach was safe, induced immune responses and disease stability. However, rapid development of Nabs prevented effective gene transfer after the second dose, even with a dose interval as short as 7 days...
  42. pmc Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan)
    Guanjun Cheng
    Thoracic Oncology Research Laboratory, University of Pennsylvania, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104 4318, USA
    J Biol Chem 285:10553-62. 2010
    ..This information also expands our knowledge on the mechanisms of action of the anti-tumor agent DMXAA (currently in clinical trials) and may be important for its biological activity...
  43. pmc CCL2 blockade augments cancer immunotherapy
    Zvi G Fridlender
    Thoracic Oncology Research Laboratory and Department of Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6160, USA
    Cancer Res 70:109-18. 2010
    ..These observations suggest that combining CCL2 neutralization with vaccines should be considered in future immunotherapy trials...
  44. ncbi Gene expression profiling of the early pulmonary response to hyperoxia in mice
    Sandra Perkowski
    Department of Clinical Studies Philadelphia, School of Veterinary Medicine, University of Pennsylvania, 3850 Spruce Street, Philadelphia, PA 19104 6010, USA
    Am J Respir Cell Mol Biol 28:682-96. 2003
    ....
  45. ncbi A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection
    Eiji Suzuki
    Thoracic Oncology Research Laboratory, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Cancer Res 67:2351-9. 2007
    ..These data suggest that ALK5 inhibitors, such as SM16, offer significant potential for the treatment of malignant mesothelioma and possibly other cancers...
  46. pmc Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers
    Africa Wallace
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Pennsylvania, USA
    Clin Cancer Res 14:3966-74. 2008
    ..We thus hypothesized that systemic blockade of TGF-beta signaling combined with adoptive T-cell transfer would enhance the effectiveness of the therapy...
  47. ncbi Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma
    Peter DeLong
    Thoracic Oncology Research Laboratory, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 4:342-6. 2005
    ..These results have implications for the development of immunotherapy directed to the malignant pleural space, and suggest the need to tailor immunotherapy to overcome immunosuppressive mechanisms in tumor environments...
  48. ncbi Gene expression profiling of malignant mesothelioma
    Sunil Singhal
    Section of Thoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 9:3080-97. 2003
    ..Multiple normalization and analysis approaches were used. Quantitative reverse transcription-PCR and immunohistochemistry were used to validate results...
  49. ncbi Role of lateral cell-cell border location and extracellular/transmembrane domains in PECAM/CD31 mechanosensation
    David A Kaufman
    Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, USA
    Biochem Biophys Res Commun 320:1076-81. 2004
    ..These findings suggest that mechanosensitive PECAM-1 may lie downstream of a primary mechanosensor that activates a tyrosine kinase...
  50. pmc Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery
    Jarrod Predina
    Thoracic Surgery Research Laboratory, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 110:E415-24. 2013
    ..Therapeutic strategies coupling antitumor agents with inhibition of immunosuppressive cells potentially could impact the outcomes of more than 250,000 people each year...
  51. ncbi Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy
    Makoto Odaka
    Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, 19104, USA
    Mol Ther 6:210-8. 2002
    ..IFN-beta may be different in different tumor types or in different anatomic locations. However, these results demonstrate that tumor-specific CD4(+) and CD8(+) T cells are the key effector cells for tumor eradication in this model...
  52. pmc Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease
    Michael K Showe
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 69:9202-10. 2009
    ..Our results show the feasibility of using peripheral blood gene expression signatures to identify early-stage NSCLC in at-risk populations...
  53. ncbi Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature
    Arnaud Scherpereel
    Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6068, USA
    J Pharmacol Exp Ther 300:777-86. 2002
    ..This paradigm may be useful for drug targeting to endothelium in lungs, heart, and possibly other organs...
  54. ncbi Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review
    Sunil Singhal
    Section of Thoracic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 11:3974-86. 2005
    ..The markers with the strongest evidence as independent predictors of patient outcome include cyclin E, cyclin B1, p21, p27, p16, survivin, collagen XVIII, and vascular endothelial cell growth factor...
  55. pmc Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature
    Bi Sen Ding
    Department of Pharmacology, IFEM, 1 John Morgan Bldg, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA 19104 6068, USA
    Blood 106:4191-8. 2005
    ....
  56. pmc The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
    M Cecilia Crisanti
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, USA
    Mol Cancer Ther 8:2221-31. 2009
    ..These studies together suggest that panobinostat may be a useful adjunct in the treatment of thoracic malignancies, especially SCLC...
  57. pmc Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation
    Bi Sen Ding
    Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Am J Respir Crit Care Med 180:247-56. 2009
    ..Diverse forms of pulmonary and vascular injury are accompanied by down-regulation of TM, which aggravates tissue injury. We postulated that anchoring TM to the endothelial surface would restore its protective functions...
  58. pmc PECAM-1 (CD31) regulates a hydrogen peroxide-activated nonselective cation channel in endothelial cells
    Guangju Ji
    Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    J Cell Biol 157:173-84. 2002
    ..PECAM-1-dependent H2O2 currents and associated [Ca2+]i transients may play a significant role in regulating neutrophil-endothelial interaction, as well as in oxidant-mediated endothelial response and injury...
  59. ncbi Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide
    Vladimir V Shuvaev
    Institute for Environmental Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6068, USA
    J Pharmacol Exp Ther 323:450-7. 2007
    ..Endothelial targeting of SOD represents a new molecular antioxidant approach that could be used for the management of vascular oxidative stress...
  60. pmc Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells
    Richard G Carroll
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    PLoS ONE 3:e3289. 2008
    ..These preclinical data suggest that human IL-18 may have use as an adjuvant for immune reconstitution after cytotoxic therapies, and to augment adoptive immunotherapy, donor leukocyte infusions, and vaccine strategies...
  61. ncbi A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma
    Anil Vachani
    University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 13:2905-15. 2007
    ..The distinction between a lung metastasis and a primary LSCC is currently based on certain clinical and histologic criteria, although the accuracy of this approach remains in question...
  62. pmc Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies
    Thomas D Dziubla
    Institute for Environmental Medicine, University of Pennsylvania Medical Center, 1 John Morgan Building, 36th Street and Hamilton Walk, Philadelphia, PA 19104 6068, USA
    Biomaterials 29:215-27. 2008
    ..Vascular targeting of PNC-loaded detoxifying enzymes may find wide medical applications including management of oxidative stress and other toxicities...
  63. pmc Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
    Carmine Carpenito
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 106:3360-5. 2009
    ..Genetically redirected T cells have promise of targeting T lymphocytes to tumor antigens, confer resistance to the tumor microenvironment, and providing immunosurveillance...
  64. pmc Vascular immunotargeting of glucose oxidase to the endothelial antigens induces distinct forms of oxidant acute lung injury: targeting to thrombomodulin, but not to PECAM-1, causes pulmonary thrombosis and neutrophil transmigration
    Melpo Christofidou-Solomidou
    Department of Medicine, Pulmonary Critical Care Division, The Institute of Environmental Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 6068, USA
    Am J Pathol 160:1155-69. 2002
    ..In particular, anti-TM/GOX causes lung injury combining oxidative, prothrombotic, and inflammatory components characteristic of the complex pathological picture seen in human ALI/ARDS...
  65. ncbi Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation
    Stephanie V Blank
    Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Hum Gene Ther 13:627-39. 2002
    ..These results suggest that replication-selective HSV-1 mutants may be potent oncolytic agents for the treatment of cervical cancer...
  66. ncbi Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey
    Assunta De Rienzo
    Human Genetics Program, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    J Cell Biochem 84:455-9. 2002
    ..We detected SV40 sequences in 4 of 11 specimens from the United States, but in none of the 9 Turkish samples examined. These findings suggest that geographical differences exist with regard to the involvement of SV40 in human tumors...
  67. ncbi BRAF and RAS mutations in human lung cancer and melanoma
    Marcia S Brose
    Department of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Cancer Res 62:6997-7000. 2002
    ..Although uncommon, BRAF mutations in human lung cancers may identify a subset of tumors sensitive to targeted therapy...
  68. pmc Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature
    Bi Sen Ding
    Department of Pharmacology, Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, USA
    Blood 111:1999-2006. 2008
    ..Endothelium-targeted thromboprophylaxis triggered by a prothrombotic enzyme illustrates a novel approach to time- and site-specific regulation of proteolytic reactions that can be modulated for therapeutic benefit...
  69. ncbi Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells
    Rainer Wiewrodt
    Pulmonary Critical Care Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Blood 99:912-22. 2002
    ..Thus, engineering of affinity carriers of specific size permits intracellular delivery of active cargoes to endothelium in vitro and in vivo, a paradigm useful for the targeting of drugs, genes, and toxins...
  70. pmc Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes
    Carmen Garnacho
    Department of Pharmacology, University of Pennsylvania Medical School, Philadelphia, PA, USA
    J Control Release 130:226-33. 2008
    ..Therefore, endothelial binding, endocytosis, and intracellular transport of anti-PECAM/NCs are epitope-specific. This paradigm will guide the design of endothelial drug delivery systems providing specific cellular localizations...
  71. ncbi PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis
    Cunji Gao
    Laboratories of PECAM 1 Research and Cell Biology, Blood Research Institute, The Blood Center of Southeastern Wisconsin, PO Box 2178, 638 N 18th St, Milwaukee, WI 53201, USA
    Blood 102:169-79. 2003
    ....
  72. ncbi Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling
    Sunil Singhal
    Section of General Thoracic Surgery, Division of Cardiothoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania USA
    Cancer Biol Ther 2:566-71. 2003
    ..Genomic profiling was used to compare gene expression levels in early stage lung adenocarcinomas and nonneoplastic pulmonary tissue in order to comprehensively identify alterations in the process of apoptosis...
  73. ncbi Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury
    Benjamin D Kozower
    Division of Cardiothoracic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
    Nat Biotechnol 21:392-8. 2003
    ..Potential applications of this strategy include improving the outcome of clinical lung transplantation and treating a wide variety of endothelial disorders...
  74. ncbi Platelet endothelial cell adhesion molecule-1 in neutrophil emigration during acute bacterial pneumonia in mice and rats
    Sadatomo Tasaka
    Department of Pediatrics, Rainbow Babies and Children s Hospital, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Am J Respir Crit Care Med 167:164-70. 2003
    ..These studies indicate that either CD11/CD18-dependent or -independent adhesion pathways may lead to PECAM-1-independent transendothelial migration through the pulmonary or the bronchial endothelium...
  75. ncbi TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials
    Steven M Albelda
    J Clin Oncol 22:577-9. 2004
  76. ncbi ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface
    Juan Carlos Murciano
    Institute of Environmental Medicine, Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    Blood 101:3977-84. 2003
    ..Enhanced drug delivery to sites of inflammation and the potential anti-inflammatory effect of blocking ICAM-1 may enhance the benefit of this targeting strategy...
  77. ncbi Microarray data simulator for improved selection of differentially expressed genes
    Sunil Singhal
    Section of Thoracic Surgery, Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania USA
    Cancer Biol Ther 2:383-91. 2003
    ..We provide access to the microarray hybridization simulator as a public resource for biologists to further test new emerging genomic bioinfomatic tools...
  78. ncbi Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response
    Pratima Sinha
    Department of Biological Sciences, University of Maryland, Baltimore County, Baltimore, MD 21250, USA
    J Immunol 179:977-83. 2007
    ....

Research Grants16

  1. TRAINING IN PULMONARY IMMUNOLOGY
    Steven Albelda; Fiscal Year: 2007
    ..D. researchers to apply. Continued efforts to increase minority recruitment are also planned. ..
  2. The Role of PECAM in Models of Lung Injury
    Steven Albelda; Fiscal Year: 2005
    ..These studies will fill a gap in the basic understanding of lung and cell adhesion biology, as well as provide potentially useful therapeutic information. ..
  3. The Role of PECAM in Models of Lung Injury
    Steven Albelda; Fiscal Year: 2004
    ..These studies will fill a gap in the basic understanding of lung and cell adhesion biology, as well as provide potentially useful therapeutic information. ..
  4. The Role of PECAM in Models of Lung Injury
    Steven Albelda; Fiscal Year: 2003
    ..These studies will fill a gap in the basic understanding of lung and cell adhesion biology, as well as provide potentially useful therapeutic information. ..
  5. The Role of PECAM in Models of Lung Injury
    Steven Albelda; Fiscal Year: 2002
    ..These studies will fill a gap in the basic understanding of lung and cell adhesion biology, as well as provide potentially useful therapeutic information. ..
  6. PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION
    Steven Albelda; Fiscal Year: 2002
    ....
  7. PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION
    Steven Albelda; Fiscal Year: 2001
    ....
  8. PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION
    Steven Albelda; Fiscal Year: 2000
    ....
  9. HUMAN-MOUSE CHIMERAS--A MODEL FOR VASCULAR CELL BIOLOGY
    Steven Albelda; Fiscal Year: 1993
    ..This information, along with the ability to test the ability of specific agents to induce or inhibit leukocyte emigration in a human in vivo model, will be extremely useful in designing novel therapeutic agents...
  10. PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION
    Steven Albelda; Fiscal Year: 1999
    ....